Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 217

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 217
---
,325)$681,427 Nine Months Ended September 30, 2024         Balances at December 31, 2023129,530$130 $1,554,634 $(2,108)$(930,584)$622,072 Issuance of common stock upon exercise of stock options515-3,925--3,925Issuance of common stock upon release of restricted stock awards, net of statutory tax withholdings1,1151(8,827)--(8,826)Issuance of common stock under Employee Stock Purchase Plan185-1,760--1,760Stock compensation expense--39,615--39,615Total other comprehensive income---2,622-2,622Net income----20,25920,259Balances at September 30, 2024131,345$131 $1,591,107 $514 $(910,325)$681,427 

See accompanying notes.

7

Dynavax Technologies Corporation 

Condensed Consolidated Statements of Cash Flows 

(In thousands) 

(Unaudited) 

Nine Months Ended September 30,20252024Operating activitiesNet (loss) income$(50,451)$20,259 Adjustments to reconcile net (loss) income to net cash provided by operating activities:    Depreciation and amortization3,706 3,443 Amortization of right-of-use assets2,463 2,538 Inventory write off3,638 1,264 Sublease termination loss (Note 5)- 4,765 Accretion of discounts on marketable securities(5,034)(11,892)Stock-based compensation expense39,824 39,615 Bad debt expense (Note 6)10,970 - Non-cash interest expense820 2,272 Loss on debt extinguishment82,095 - Changes in operating assets and liabilities:    Accounts and other receivables, net(26,415)(30,744)Inventories(6,872)(10,376)Prepaid manufacturing- (6,893)Prepaid expenses and other current assets(2,260)(2,643)Other assets- (878)Accounts payable(5,148)2,023 Lease liabilities(3,151)(3,220)Accrued and other liabilities(6,564)3,968 Net cash provided by operating activities37,621